CH
AXSM icon

Cromwell Holdings’s Axsome Therapeutics AXSM Stock Holding History

Cromwell Holdings’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.03K Hold
11
– – ﹤0.01% 907
2026
Q2 		$2.69K Buy
+11
New +$2.39K ﹤0.01% 788

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Cromwell Holdings's AXSM Position: Q3 2026 in Review

Cromwell Holdings held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 11 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Cromwell Holdings first reported a position in AXSM in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.69K in Q2 2026. 235 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Cromwell Holdings held 11 shares of Axsome Therapeutics worth $2.03K as of Q3 2026.
  • Cromwell Holdings left its Axsome Therapeutics share count unchanged in Q3 2026.
  • Axsome Therapeutics made up ﹤0.01% of Cromwell Holdings's portfolio in Q3 2026, its #907 holding.
  • Cromwell Holdings first reported a position in Axsome Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Cromwell Holdings's Axsome Therapeutics position peaked at $2.69K in Q2 2026.
  • 235 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Cromwell Holdings's 13F filing for Q3 2026, filed 28 Oct 2026.